HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo's Evidence For Nasal Spray Claims Not Enough For ASA

Executive Summary

Ad claims that Perrigo’s BecoCleanse could protect against viruses to help prevent the occurrence of cold symptoms were not supported by sufficient evidence, the UK’s Advertising Standards Authority has ruled.

You may also be interested in...



EU Regulators Clarify Rules On Nasal Spray Claims Ahead Of Cold & Flu Season

The EU's medical device regulators have joined forces to remind consumer health firms of the rules which must be followed when marketing a nasal spray offering protection from viruses, such as influenza and SARS-CoV-2.

Michigan Firm’s Nasal Spray Neither A COVID-19 Treatment Nor For Nasal Use

CofixRx and Sensory Cloud are latest OTC nasal spray marketers FDA warned about fraudulent COVID-19 claims. While the others’ violations were limited to violative claims, CofixRx also warned the active ingredient in its spray is limited to topical use.

Latest Test Of US FTC’s Standard Of RCTs For Health Claims: Saline Nasal Spray And COVID-19

Xlear founder Nate Jones says FTC doesn’t argue that results and other information in research linked in social media posts, its website and a press release are false, but wants to prohibit providing information to consumers on research about preventing and treating COVID-19.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS153051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel